Home › Funds › Lion Point Capital, LP › PCRX

Lion Point Capital, LP position in PCRX

PACIRA BIOSCIENCES INC COM · Health Care

Lion Point Capital, LP reported holding 13,500 shares of PCRX (PACIRA BIOSCIENCES INC COM) in its Q2 2026 13F filing — a position valued at US$342K, representing 1.64% of its reported portfolio and ranking #23 among its reported holdings. Lion Point Capital, LP has disclosed PCRX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)13.50K sh
Reported value held$342.50K
Portfolio Weight1.64%
First reportedQ4 2025
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Lion Point Capital, LP's PCRX position evolved

Lion Point Capital, LP first disclosed a stake in PCRX in Q4 2025 at 13,500 shares (US$349K). Across 3 filings, Lion Point Capital, LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 13,500 shares valued at US$342K.

Quarter by quarter

QuarterSharesValueChange
Q4 2025 13.50K $349.38K New
Q1 2026 13.50K $305.10K Hold
Q2 2026 13.50K $342.50K Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About PCRX and 13F data

PCRX (PACIRA BIOSCIENCES INC COM) is a Health Care company. 24 other funds we track also report a position in PCRX — the largest reported positions include Context Capital Management, LLC (US$88.7M), Doma Perpetual Capital Management LLC (US$70.5M), GAGNON SECURITIES LLC (US$15.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding PCRX

All PCRX fund holders →

FAQ

How long has Lion Point Capital, LP held PCRX?

Lion Point Capital, LP has disclosed PCRX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

What is Lion Point Capital, LP's current position in PCRX?

As of Q2 2026, Lion Point Capital, LP holds 13.50K shares of PCRX (PACIRA BIOSCIENCES INC COM), valued at $342.50K, representing 1.64% of its reported portfolio and ranking #23.

Has Lion Point Capital, LP been buying or selling PCRX?

In the latest 13F filing (Q2 2026), Lion Point Capital, LP held unchanged its position in PCRX.

Which other funds hold PCRX?

Other major institutional holders of PCRX include Context Capital Management, LLC, Doma Perpetual Capital Management LLC, GAGNON SECURITIES LLC, among 24 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.